Meeting
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
Authors
Biagio Ricciuti
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA
Biagio Ricciuti , Arielle Elkrief , Joao Victor Machado Alessi , Xinan Wang , Adriana Paula de Castro Barrichello , Federica Pecci , Giuseppe Lamberti , James Lindsay , Bijaya Sharma , Kristen Felt , Mizuki Nishino , Lynette M. Sholl , Scott J. Rodig , Adam Jacob Schoenfeld , Mark M. Awad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9043)
DOI
10.1200/JCO.2022.40.16_suppl.9043
Abstract #
9043
Poster Bd #
31
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.
First Author: Petros Christopoulos
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2022 ASCO Annual Meeting
Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Biagio Ricciuti
Poster
2022 ASCO Annual Meeting
A pancancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB).
First Author: Wafik S. El-Deiry